John E. Knox - Concepedia

Author

John E. Knox

Revolution Medicines (United States)ORCID

Also Known As

J E. Knox, J. E. Knox, J. Knox, J.E. Knox, John E. Knox, John Knox, John E. Knox, Knox, J.E., Wang, Yingyun

125

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

Revolution Medicines (United States)Wayne State University Novartis (Singapore)Memorial Sloan Kettering Cancer Center Harvard University

About

John E. Knox is an author at Revolution Medicines (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	13	627
2	Engineering	7	7	132
3	Biochemistry	7	7	387
4	Natural Sciences	6	6	235
5	Biomolecular Engineering	4	4	112

John E. Knox

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy Matthew Holderfield, Bianca J. Lee, Jingjing Jiang, Nature	2024	268
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers Jingjing Jiang, Lingyan Jiang, Benjamin J. Maldonato, Cancer Discovery	2024	231
Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS Christopher J. Schulze, Kyle J. Seamon, Yulei Zhao, Science	2023	203
Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde inhibitors Zheng Yin, Sejal Patel, Weiling Wang, Bioorganic & Medicinal Chemistry Letters Antiviral CompoundBiochemistryAntiviral Drug DevelopmentSar StudyVirology	2005	152
Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis Mekonnen Kurabachew, Shuihua Lu, Philipp Krastel, Journal of Antimicrobial Chemotherapy	2008	99
Peptide Inhibitors of West Nile NS3 Protease: SAR Study of Tetrapeptide Aldehyde Inhibitors John E. Knox, Ngai Ling, Zheng Yin, Journal of Medicinal Chemistry Crystal StructureProtein AssemblyBiomolecular Structure PredictionMolecular BiologyViral Structural Protein	2006	85
Chemical failure modes of AlQ3-based OLEDs: AlQ3 hydrolysis John E. Knox, Mathew D. Halls, Hrant P. Hratchian, Physical Chemistry Chemical Physics	2006	72
Synthesis and antitubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazines, analogues of PA-824 Xiaojin Li, Ujjini H. Manjunatha, Michael Goodwin, Bioorganic & Medicinal Chemistry Letters Antitubercular ActivityBioorganic ChemistryHeterocyclicBiochemistryNatural Sciences	2008	68
Abstract 526: RMC-9805, a first-in-class, mutant-selective, covalent and oral KRASG12D(ON) inhibitor that induces apoptosis and drives tumor regression in preclinical models of KRASG12D cancers Lingyan Jiang, Marie Ménard, Caroline E. Weller, Cancer Research Oral Krasg12dTumor BiologyKrasg12d NsclcChemoprevention StrategyMedicine	2023	61
Finding New Medicines for Flaviviral Targets Thomas H. Keller, Yen‐Liang Chen, John E. Knox, Novartis Foundation symposium Medicinal ChemistryNs3 ProteasesMedicineAntiviral Drug DevelopmentAntiviral Therapy	2006	52

Page 1